Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 13/20 | 0.87 |
| ▸ | AR | P10275 | 5/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7181681 | 0.93 | VDR (1.00) | VDRARHDAC6HDAC3 | |
| SCHEMBL29754394 | 0.93 | VDR (1.00) | VDRARHDAC6HDAC3 | |
| SCHEMBL16183080 | 0.91 | VDR (0.89) | VDRARHDAC6HDAC3 | |
| SCHEMBL2944811 | 0.90 | VDR (0.87) | VDRARHDAC6HDAC3ESR1 | |
| SCHEMBL2973082 | 0.88 | VDR (0.85) | VDRARHDAC6HDAC3 | |
| SCHEMBL14254352 | 0.88 | VDR (0.85) | VDRARHDAC6HDAC3 | |
| SCHEMBL16183037 | 0.88 | VDR (0.89) | VDRARHDAC6HDAC3 | |
| SCHEMBL16177773 | 0.88 | VDR (0.89) | VDRARHDAC6HDAC3 | |
| SCHEMBL2947701 | 0.87 | VDR (0.66) | VDRARHDAC6HDAC3ESR1 | |
| SCHEMBL2965724 | 0.87 | VDR (0.82) | VDRARHDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794556-B1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | GLEASON JAMES L (CA) | 2018-04-18 | — | — | EP | disclosed |
| US-9428447-B2 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-08-30 | — | — | US | disclosed |
| US-9428447-B2 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-08-30 | — | — | US | disclosed |
| US-9428447-B2 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-08-30 | — | — | US | disclosed |
| EP-2794556-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | KALDRE, Dainis (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | KALDRE, Dainis (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | KALDRE, Dainis (CA) | 2014-10-23 | — | — | US | disclosed |
| WO-2013091082-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | VDR, CYP2R1, CYP24A1 | VDR 1/4885AR 24/4885HDAC6 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.